CH BIOTECH SER (08037) plans to issue convertible bonds with a total principal amount of 35 million US dollars to Fuche Holdings.

CH BIOTECH SER (08037) announced that on December 29, 2025, the company entered into a subscription agreement with the subscriber Fuche Holdings. The company has conditionally agreed to issue convertible bonds with a principal amount of $35 million (equivalent to approximately HK$272.3 million), while the subscriber has conditionally agreed to subscribe for them. Based on a preliminary conversion price of HK$0.66 per share (subject to adjustments), a maximum of 412.6 million shares will be issued when the conversion rights attached to the convertible bonds are exercised. This represents approximately 42.28% of the total number of issued shares as of the date of this announcement and approximately 29.72% of the total number of issued shares after the conversion of the convertible bonds (assuming no changes in issued capital from the date of this announcement until the conversion of the convertible bonds at the preliminary conversion price). The subscriber is mainly engaged in investment businesses, with a managed asset size of over $100 million in industries such as life sciences, pharmaceuticals, education, internet, technology media, and telecommunications. The Board believes that strengthening the group's capital base through the subscription will prepare the group for long-term development and further enhance its financial position. The issuance of convertible bonds will not have an immediate dilutive effect on existing shareholders' equity. The Board also believes that if the conversion rights attached to the convertible bonds are exercised, the issuance will provide the company with the opportunity to expand and strengthen its capital base, as well as broaden its shareholder base by introducing new investors.